Home・Akcijų sąrašas・Vir Biotechnology Inc

Vir Biotechnology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

9.19 2.22

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.92

Max

9.19

Pagrindiniai rodikliai
By Trading Economics
Pajamos	80M -46M
Pardavimai	239M 239M
Pelnas, tenkantis vienai akcijai	0.47
Pelno marža	-19.09
Darbuotojai	367
EBITDA	201M 78M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+136.56% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3.3M 1.5B
Ankstesnė atidarymo kaina	6.97
Ankstesnė uždarymo kaina	9.19

Naujienos nuotaikos

By Acuity

20%

80%

46 / 340 reitingas Healthcare

Vir Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-11 19:36; UTC

Vir Biotechnology Inc. shares are trading roughly flat amid geopolitical tensions and anticipation of U.S. inflation reports that could influence Federal Reserve policy.

2026-08-10 23:56; UTC

Vir Biotechnology Inc. shares advanced in after-market trading, reflecting a modest increase from Monday's close, though still below the 20-day moving average.

2026-08-07 19:36; UTC

Correlated Moves

Vir Biotechnology shares are higher, supported by broader market gains and a notable increase in the ARK Genomic Revolution ETF.

2026-08-06 23:21; UTC

Vir Biotechnology Inc shares are higher in after-market trading, showing positive momentum following Thursday's close. No specific news was identified to explain the movement.

2026-08-05 23:41; UTC

News

Social Media

Vir Biotechnology reported second-quarter revenue of $238.9 million, exceeding estimates, contributing to significant gains in after-market trading.

2026-08-03 19:46; UTC

Vir Biotechnology Inc's shares are higher today, reflecting broader market trends amid falling oil prices. The stock remains below its 20-day moving average.

2026-07-30 19:58; UTC

Vir Biotechnology Inc shares are higher today amid a broader recovery in tech stocks, despite breaking a recent trend of higher daily closes.

2026-07-29 19:27; UTC

Shares of Vir Biotechnology Inc. are trading lower today, having declined after an initial uptick and hitting a session low in late morning.

2026-07-28 15:46; UTC

Correlated Moves

Shares lower today, pressured by declines in biotech sector.

2026-07-27 20:07; UTC

Vir Biotechnology's shares are higher today, continuing gains since Friday. The broader market is influenced by declining oil prices and lower Treasury yields.

2026-07-25 00:01; UTC

Vir Biotechnology Inc shares are higher in after-market trading, recovering from earlier lows. The stock is near the lower end of its one-month trading range.

2026-07-24 23:31; UTC

Vir Biotechnology Inc shares are higher in after-market trading, reflecting notable gains since Friday's close, despite no specific news driving the price action.

2026-07-21 17:16; UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher today, supported by a positive trend in the broader biotech sector. Earlier, shares pulled back but have since recovered.

2026-07-20 21:02; UTC

Vir Biotechnology Inc shares fell during after-market hours amid broader market declines following a reported drop in the Leading Economic Index for June.

Akcijų palyginimas

Kainos pokytis

Vir Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

136.56% į viršų

12 mėnesių prognozė

Vidutinis 21.29 USD 136.56%

Aukščiausias 30 USD

Žemiausias 15 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Vir Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Vir Biotechnology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

46 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.